CytoDyn Inc (PK:CYDY)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 1111 Main St Ste 660 VANCOUVER WA 98660-2970 |
| Tel: | N/A |
| Website: | https://www.cytodyn.com |
| IR: | See website |
| Key People | ||
| Tanya Durkee Urbach Independent Chairman of the Board | Jacob P. Lalezari Chief Executive Officer | Mitchell Cohen Interim Chief Financial Officer | Tyler Blok Executive Vice President - Legal Affairs, Joint Company Secretary |
| Business Overview |
| CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors. |
| Financial Overview |
| For the nine months ended 29 February 2024, CytoDyn Inc revenues was not reported. Net loss decreased 46% to $33.1M. Lower net loss reflects Loss on derivatives decrease of 89% to $971K (expense), Finance charges decrease of 65% to $2.7M (expense), General and administrative - Balancing decrease of 48% to $4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.08 to -$0.03. |
| Employees: | 12 as of May 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $166.05M as of Feb 29, 2024 |
| Annual revenue (TTM): | $0.00M as of Feb 29, 2024 |
| EBITDA (TTM): | -$15.17M as of Feb 29, 2024 |
| Net annual income (TTM): | -$51.69M as of Feb 29, 2024 |
| Free cash flow (TTM): | -$12.74M as of Feb 29, 2024 |
| Net Debt Last Fiscal Year: | $28.77M as of Feb 29, 2024 |
| Shares outstanding: | 993,366,000 as of Mar 31, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.